Is polycystic ovary syndrome associated with high sympathetic nerve activity and size at birth?

Yrsa Bergmann Sverrisdóttir1, Tove Mogren, Josefin Kataoka

  • 1Institute of Neuroscience and Physiology, Dept. of Physiology, Sahlgrenska Academy, Göteborg Univ., Box 432, SE-405 30 Göteborg, Sweden. yrsa.sverrisdottir@neuro.gu.se

Insights

Polycystic ovary syndrome (PCOS) is linked to heightened sympathetic nerve activity, a key factor in cardiovascular risk. This study found increased muscle sympathetic nerve activity (MSNA) in women with PCOS, influenced by testosterone and cholesterol levels.

Area of Science:

  • Endocrinology
  • Cardiovascular Physiology
  • Neuroscience

Background:

  • Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder in women of reproductive age.
  • PCOS is associated with metabolic disturbances and increased cardiovascular disease risk.
  • Sympathetic nervous system dysfunction is implicated in the etiology of PCOS.

Purpose of the Study:

  • To evaluate sympathetic nervous system outflow in women with PCOS.
  • To investigate the relationship between sympathetic activity and PCOS.
  • To explore the connection between sympathetic activity, hormonal levels, and birth size in PCOS.

Main Methods:

  • Directly recorded muscle sympathetic nerve activity (MSNA) in 20 women with PCOS and 18 controls.
  • Assessed ovarian ultrasonography, biometric, hormonal, and biochemical parameters.
  • Collected and analyzed birth data for all participants.

Main Results:

  • Women with PCOS exhibited significantly higher MSNA compared to controls (30 ± 8 vs. 20 ± 7 burst frequency, P < 0.0005).
  • MSNA in PCOS was positively correlated with testosterone (r = 0.63, P < 0.005) and cholesterol (r = 0.55, P = 0.01).
  • Testosterone emerged as a stronger predictor of MSNA than cholesterol; birth size did not differ between groups.

Conclusions:

  • PCOS is associated with elevated sympathetic nerve activity (MSNA).
  • Testosterone and cholesterol levels are independent predictors of MSNA in PCOS, with testosterone having a greater impact.
  • Increased MSNA in PCOS may contribute to cardiovascular risk and the condition's underlying pathology.

Related Concept Videos

Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
Adrenal Gland Disorders01:27

Adrenal Gland Disorders

Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Cushing Syndrome I: Introduction01:26

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...